| EFFECTS OF THE USE OF BETA-BLOCKERS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CARDIOVASCULAR COMORBITIES: SYSTEMATIC REVIEW AND META-ANALYSIS |
|
Natasha Cordeiro dos Santos, Aquiles Assunção Camelier, Anne Karine Menezes, Victor Durier Cavalcanti de Almeida, Roberto Rodrigues Bandeira Tosta Maciel, Fernanda Warken Rosa Camelier |
|
State University of Bahia, Brazil |
Correspondence:
Natasha Cordeiro dos Santos,
Email: cordeiro@hotmail.com
|
|
Received: 27 January 2024 • Revised: 18 March 2024 • Accepted: 29 March 2024 |
| Abstract |
Introduction
Cardiovascular comorbidity is common in individuals with Chronic obstructive pulmonary disease (COPD). These factor interferes in pharmacological treatment. The use of beta-blockers has been proposed for their known cardioprotective effects. However, there is a reluctance to use them due to adverse reactions and the risk of causing bronchospasm.
Objective
To summarize existing evidences on the effects of beta-blocker use in COPD associated with cardiovascular comorbidities in relation to disease severity, exacerbation and mortality outcomes.
Material and Methods
EMBASE, Medline, Lilacs, Cochrane Library and Science Direct databases were used. Study selection and data extraction, observational studies were included that evaluated the effects of beta-blockers in individuals with COPD and cardiovascular comorbidities, and related disease severity, exacerbations, or mortality to outcomes. Studies that did not present important information about the sample and pharmacological treatment were excluded. Twenty studies were included.
Results
Relevance to patient care and clinical practice: The use of beta-blockers in individuals with COPD and cardiovascular disease caused positive effects on mortality and exacerbations outcomes compared with the results of individuals who did not use them. The severity of the disease caused a slight change in FEV1. The OR for mortality was 0.50 (95 % CI: 0.39-0.63; p-value <0.00001) and for exacerbations 0.76 (95 % CI: 0.62-0.92; p -value = 0.005), being favorable to the group that used beta-blockers.
Conclusion
Further studies are needed to study the effect of using a specific beta-blocker in COPD associated with a specific cardiovascular comorbidity. |
| Key Words:
Chronic obstructive pulmonary disease, Cardiovascular diseases, Mortality, Beta blockers, Systematic review |
|
PDF Links
Full text via DOI
Download Citation
